Polycystic Ovary Syndrome and Exercise
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03362918|
Recruitment Status : Recruiting
First Posted : December 5, 2017
Last Update Posted : December 19, 2017
Polycystic Ovary Syndrome (PCOS) is a common hormonal disorder characterized by oligo-ovulatory menstrual dysfunction, androgen excess and polycystic ovaries. It affects ten to fifteen percent of reproductive-age women and has been associated with complications in reproductive, metabolic and cardiovascular health. Current Clinical Practice Guidelines suggest exercise and weight loss for PCOS, although their specific roles in improving PCOS-related symptoms are uncertain.
Non-pharmacological treatments are appealing to many reproductive age women. There is preliminary evidence that exercise in PCOS may increase menstrual regularity, ovulation, cardiorespiratory fitness, health-related quality of life (HRQOL) and self-esteem, and decrease body fat and insulin resistance. These studies have been limited by short durations and lack of randomization or appropriate control groups.
High-intensity interval training (HIIT), which involves brief intervals of near-maximal exercise alternating with lower-intensity exercise, is becoming increasingly popular in the exercise community. In some non-PCOS trials, HIIT resulted in improved cardiovascular fitness and greater fat loss compared with continuous aerobic exercise. No other trials are currently on-going that are comparing HIIT with continuous aerobic exercise training in women with PCOS (as confirmed by searches of the literature and the clinical trials registry maintained by the US NIH).
|Condition or disease||Intervention/treatment||Phase|
|Polycystic Ovary Syndrome||Behavioral: High Intensity Interval Training Behavioral: Continuous Aerobic Exercise Training||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||The outcome assessors will be blind to the allocation of the study participants.|
|Official Title:||The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.|
|Estimated Study Start Date :||January 1, 2018|
|Estimated Primary Completion Date :||December 1, 2019|
|Estimated Study Completion Date :||December 1, 2019|
No Intervention: Control Group
Participants randomized to the control group will continue with their usual level of physical activity. They will track their menstrual cycles and perform daily ovulation tests.
Once all post-intervention assessments are complete, they will have the option to begin an exercise program with three supervised sessions of either high-intensity interval training or continuous aerobic exercise training free of charge. They will be given a Polar heart rate (HR) monitor as a gift for their participation in the study.
Experimental: High-Intensity Interval Training
Participants randomized to this group will complete three high intensity interval training sessions per week, two of which will be supervised. They will exercise for a total of 30 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool-down.
Behavioral: High Intensity Interval Training
The exercise prescription is as follows:
Type: High-Intensity Interval Training on a treadmill, elliptical trainer or cycle ergometer.
Intensity: 30 seconds of high-intensity alternating with 90 seconds of low intensity for a total of 10 cycles
Duration: 30 minutes Frequency: 3 times per week
Experimental: Continuous Aerobic Exercise Training
Participants randomized to this group will complete three continuous aerobic training sessions per week, two of which will be supervised. They will exercise for a total of 50 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool down.
Behavioral: Continuous Aerobic Exercise Training
The exercise prescription for the continuous aerobic exercise group is as follows:
Type: Aerobic exercise including walking, running, cycling or using the elliptical trainer.
Intensity: Moderate intensity, defined as 50-60% of the participant's maximum heart rate. On the rating of perceived exertion scale, this corresponds with a 4-6/10, which allows participants to hold a conversation while breathing heavily.
Duration: 50 minutes Frequency: 3 times per week
- Ovulation Rate [ Time Frame: Up to 9 months. ]The ovulation rate is defined as the number of times a participant ovulates during the intervention period adjusted for the baseline ovulation rate during the run-in phase.
- Hirsutism [ Time Frame: Up to 9 months. ]This will be assessed using the Ferriman-Gallwey Score, which quantifies hair growth in women with PCOS. Scores range from 0-36, with higher scores indicating more hair growth.
- Menstrual Cycle Length [ Time Frame: Up to 9 months. ]The menstrual cycle starts on the first day of menses and lasts until menses resumes. A regular menstrual cycle length ranges from 24 to 35 days.
- Luteal Phase Length [ Time Frame: Up to 9 months. ]The luteal phase length is defined as the number of days from ovulation to menses (normal is 12 to 16 days).
- Pregnancy [ Time Frame: Up to 15 months. ]Pregnancy will be confirmed by the presence of a fetal heart beat on a first-trimester ultrasound, ordered by the participant's physician.
- Spontaneous Abortions [ Time Frame: Up to 15 months. ]Non-induced embryonic or fetal death or passage of products of conception before 20 weeks gestation.
- Live Births [ Time Frame: Up to 15 months. ]The delivery of a live infant
- Body Weight [ Time Frame: Up to 9 months. ]Change in body weight pre- and post-intervention
- Body Mass Index [ Time Frame: Up to 9 months. ]Change in body mass index pre- and post-intervention
- Waist Circumference [ Time Frame: Up to 9 months. ]Change in waist circumference pre- and post-intervention
- Blood Pressure [ Time Frame: Up to 9 months. ]Change in blood pressure pre- and post-intervention
- Hemoglobin A1c [ Time Frame: Up to 9 months. ]Change in hemoglobin A1c pre- and post-intervention
- Fasting Glucose [ Time Frame: Up to 9 months. ]Change in fasting glucose pre- and post-intervention
- Fasting Insulin [ Time Frame: Up to 9 months. ]Change in fasting insulin pre- and post-intervention
- Homeostatic Model of Insulin Resistance (HOMA-IR) [ Time Frame: Up to 9 months. ]Change in HOMA-IR pre- and post-intervention
- HOMA-2 [ Time Frame: Up to 9 months. ]To assess insulin resistance using the updated HOMA-2 model
- Lipids - total cholesterol, LDL, HDL, triglycerides [ Time Frame: Up to 9 months. ]Change in lipid profile pre- and post-intervention
- Liver Enzymes - ALT, GGT [ Time Frame: Up to 9 months. ]Change in liver enzymes pre- and post-intervention
- Cardiorespiratory Fitness [ Time Frame: Up to 9 months. ]Change in cardiorespiratory fitness assessed as maximal oxygen consumption evaluated using a treadmill test and a metabolic cart
- Health-Related Quality of Life [ Time Frame: Up to 15 months. ]Change in Health-Related Quality of Life using the PCOS-Q
- Obstructive Sleep Apnea [ Time Frame: Up to 9 months. ]Change in symptoms of obstructive sleep apnea pre- and post-intervention using the STOP-BANG score. This score has 8 questions, and the likelihood of obstructive sleep apnea increases with a score of 3 or more.
- Participant Satisfaction [ Time Frame: Up to 9 months. ]To assess participant satisfaction with their participation in this study using a questionnaire specifically designed for this study, with higher numbers indicating higher satisfaction.
- Participant Recruitment - Number of Participants Screened [ Time Frame: Up to enrolment in study. ]Participant recruitment will be assessed by recording the number of participants that were initially screened.
- Participant Recruitment - Recruitment Method [ Time Frame: Up to enrolment in study. ]The investigators will document how each participant was recruited (i.e. poster, physician referral, etc.).
- Participant Recruitment - Number of Participants That Met Criteria [ Time Frame: Up to enrolment in the study. ]The investigators will record the number that met all inclusion and exclusion criteria.
- Participant Recruitment - Number of Participants That Signed Informed Consent [ Time Frame: Up to enrolment in the study. ]The investigators will record the number that agreed to participate in the study and signed informed consent.
- Participant Dropout [ Time Frame: Up to 15 months. ]Dropout will be reported as a percentage of participants that enrolled in the study and did not complete the study.
- Adherence to Menstrual Cycle Tracking [ Time Frame: Up to 9 months. ]Participants will record features of their menstrual cycle daily (menses, spotting, no menstrual bleeding) using a monthly calendar, or phone app. Adherence will be recorded as the percentage of data recorded over the study duration.
- Adherence to Ovulation Prediction Kit (OPK) Testing [ Time Frame: Up to 9 months. ]Participants will complete the OPK test daily, take a digital photograph of the used test strip and send it to the research team daily. Adherence will be recorded as the percentage completed over the study.
- Adherence to Exercise Sessions [ Time Frame: Up to 9 months. ]For individuals randomized to the high-intensity training group or the continuous aerobic exercise training group, exercise sessions will be tracked using a Polar heart rate monitor and data will be downloaded weekly at a supervised exercise session. Participants will also log their workouts (type, duration, intensity) in a log book.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03362918
|Contact: Jamie L Benham, MDfirstname.lastname@example.org|
|University of Calgary Clinical Trials Unit||Recruiting|
|Calgary, Alberta, Canada, T2T 5C7|
|Contact: Jamie L Benham, MD 4039558325 email@example.com|
|Principal Investigator:||Ronald J Sigal, MD, MPH||University of Calgary, firstname.lastname@example.org|